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Glycosphingolipids (GSLs) GM3 (NeuAca3Galb4Glcb1Cer) and GM2 (GalNAcb4[NeuAca3]Galb4Glcb
1Cer) inhibit (i) cell growth through inhibition of tyrosine kinase associated with growth factor
receptor (GFR), (ii) cell adhesion/motility through inhibition of integrin-dependent signaling via
Src kinases, or (iii) both cell growth and motility by blocking ‘‘cross-talk” between integrins and
GFRs. These inhibitory effects are enhanced when GM3 or GM2 are in complex with speciﬁc tetraspa-
nins (TSPs) (CD9, CD81, CD82). Processes (i)–(iii) occur through speciﬁc organization of GSLs with key
molecules (TSPs, caveolins, GFRs, integrins) in the glycosynaptic microdomain. Some of these pro-
cesses are shared with epithelial–mesenchymal transition induced by TGFb or under hypoxia, partic-
ularly that associated with cancer progression.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Some early studies during the 1970s and 1980s indicated that
speciﬁc glycosphingolipids (GSLs) are located at speciﬁc domains
of cellular membranes, e.g., fucose-containing GSLs at apical micro-
villi membrane, but not at basolateral membrane of intestinal epi-
thelial cells [1]. GM3 (NeuAca3Galb4Glcb1Cer) is present in higher
concentration at cell adhesion sites than at other membrane sites
of BHK ﬁbroblasts, and GM3 at the adhesion site is insoluble in
non-ionic detergent [2]. Sphingolipids and GSLs interact with
non-glycosylated proteins in erythrocyte membrane, are insoluble
in non-ionic detergent, and display speciﬁc morphological proﬁle
observed under electron microscopy [3]. At that time, the molecu-
lar basis of cell polarity became one of the major topics in cell biol-
ogy. Speciﬁc expression of a glycoprotein, hemagglutinin, waschemical Societies. Published by E
T, epithelial–mesenchymal
FN, ﬁbronectin; GFR, growth
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Paciﬁc Northwest Research
: +1 206 726 1212.observed after inﬂuenza virus infection at apical site, but not baso-
lateral site, of kidney epithelial MDCK cells. A search for possible
sorting mechanism indicated that hemagglutinin is delivered di-
rectly to the apical surface, rather than ‘‘sorting” from basolateral
site [4].
These earlier studies suggested that membrane GSLs or glyco-
proteins must be clustered, providing a basis for interaction with
other membrane components. In fact, extensive clustering of GSL
Gb4, or of glycophorin, at the surface of erythrocytes, was demon-
strated by electron microscopy through freeze/etch procedure
[5,6].
Since our long-term research interest is in the structure and
function of GSLs, deﬁning tumor growth and motility, our recent
studies have focused on organization and interaction of GSLs with
functional membrane proteins in microdomain. Results of our ma-
jor studies during the past decade, together with related studies by
other research groups, are described brieﬂy in this review.2. Microdomain having GSL/caveolin or GSL/tetraspanin,
controlling cell adhesion and motility
Following the earlier works as described above, a large number
of studies on molecular interaction of various components in
microdomains were developed during the late 1980s to earlylsevier B.V. All rights reserved.
Table 1
Contrasting properties of ‘‘raft” vs. ‘‘glycosynapse”.
Raft Glycosynapse
Mobile, ﬂoating signaling platform Less-mobile adhesion platform
May not be involved in cell adhesion (not
described so far)
Involved in GSL-dependent cell
adhesion with concurrent
signalling
Involved in control of endocytosis Unclear (no studies made)
Cholesterol-dependent (disrupted by
chol.-binding reagent, e.g., nystatin,
ﬁlipin, b-cyclodextrin)
Cholesterol-independent (less
sensitive to chol.-binding
reagent)
Tetraspanin-dependence is not reported Tetraspanin-dependent
Insoluble in 1% Triton X-100 Soluble in 1% Triton X-100, but
insoluble in 1% Brij98
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riched domains which are resistant to non-ionic detergents. Such
microdomains were variously termed as ‘‘DRM” (detergent resis-
tant membrane) (for review [7]), caveolae membrane (for review
[8]), ‘‘raft’’ (for review [9]), and ‘‘glycosignaling domain” ([10,11];
for review [12]). The term ‘‘raft’’ has been used most frequently,
to signify an rapidly-moving cell surface signaling platform.
Among various components present in microdomain, caveolin
has received great attention as a major adapter molecule affecting
cellular phenotype. A few examples are described here. Expression
of caveolin-1 may inhibit ovarian cancer progression, and its
down-regulation promotes enhanced tumor malignancy through
possible interaction with E-cadherin [13]. Caveolin-1 gene is ex-
pressed at low level in highly malignant ovarian cancer, and is
likely to act as tumor-suppressor gene in human ovarian epithelia
[14]. The inhibitory effect of caveolin-1 on tumor progression may
be based on its interaction with integrin a subunit, which causes
activation of Fyn, in turn activating Shc tyrosine phosphorylation.
This sequential process is necessary to open up the Ras/Erk path-
way, to control tumor cell motility [15]. These observations indi-
cate that caveolin-1 expression inhibits, and its down-regulation
promotes, cancer progression. However, an important question
whether gangliosides and GSLs affect caveolin function in microdo-
main was not considered before.
A recent study [16] addressed this important question. Trans-
fection of cDNA for GM3 synthase (SAT-1) to ovarian cancer
A2780 cells caused overexpression of GM3 and (to a lesser extent)
GM2 (GalNAcb4[NeuAca3]Galb4Glcb1Cer). Motility of these cells
was greatly reduced, in comparison to mock transfectant or wild-
type A2780 cells, although growth rate was not affected by
enhanced GM3. SAT-1 transfectant expressing high GM3 also dis-
played high level of caveolin-1 (but not caveolin-2 or -3) which,
however, was not accompanied by morphologically distinguish-
able caveolae. Enhancement of caveolin-1 was closely associated
with enhanced expression of GM3 and its synthase gene, since
caveolin-1 is the major target of GM3 interaction, as indicated by
binding of photoactivatable GM3. Caveolin-1, GM3, and Src are
all present in low-density membrane fraction resistant to Triton
X-100. The motility-inhibitory effect of caveolin-1 and GM3 is as-
sumed to be mediated by cSrc, since incubation of cells with Src
inhibitor, SU6656, inhibited cell motility. Motility inhibition is
associated with high GM3 level, while it was lost with low GM3 le-
vel, through caveolin-1/GM3 interaction. This study made clear
how gangliosides modulate tumor cell motility through interaction
with caveolin-1, and activation or inactivation of Src [16].
Interestingly, the motility-inhibitory effect of GM3 together
with caveolin was similar to that of GM3 complexed with tetra-
spanin (TSP) CD9 or CD82 [17–19]. However, caveolin/sphingolipid
causes speciﬁc membrane architecture and function, as summa-
rized in a recent review [20]. Functional interactions of GSLs with
various receptors in microdomains were also extensively reviewed
recently [21].
Gangliosides, particularly GM3 and GM2, are known to interact
with growth factor receptors (GFRs), and to inhibit the enhanced
tyrosine kinase activity of the receptor induced by growth factor.
Typical examples are GM3-dependent inhibition of tyrosine ki-
nases associated with epidermal GFR [22], with ﬁbroblast GFR
(FGFR) [23,24], and with insulin receptor [25,26]; for reviews see
[27,28]. GM3 also interacts with and activates cSrc, Src family ki-
nases, and G-proteins [10]. The relationship of this process with
integrin-dependent signaling was subsequently clariﬁed by studies
using ldlD cells and their CD9 transfectant [18,19].
During these studies, we noticed that physical and biochemical
properties, and functional signiﬁcance of microdomain containing
GSL/TSP complex, are different from those of ‘‘raft”. Therefore, we
applied the term ‘‘glycosynapse” or ‘‘glycosynaptic microdomain”[29,30], in analogy to ‘‘ímmunological synapse” or ‘‘ímmunosyn-
apse” [31], the molecular complex surrounding T-cell receptor
which is involved in adhesion of antigen-presenting cell to T-cell
receptor. Synaptic function, i.e., adhesion process, is involved for
both glycosynapse and ímmunosynapse. Contrasting properties
of glycosynapse vs. ‘‘raft” are summarized in Table 1.
The molecular mechanism of cancer ‘‘malignancy”, reﬂecting
enhanced cell motility with altered cell adhesion and growth, is as-
sumed to be based on organizational status of GM3 and TSP CD9 in
microdomain, as initially suggested by a study using ldlD cells (see
subsequent section). This study was extended to interaction of
GM2 with TSP CD82 to form GM2/CD82 complex. Such complex
inhibits cell motility and growth by blocking functional interaction
(‘‘cross-talk”) between integrin a3 and cMet [32], or between a3
and FGFR [24]. A basic concept of GSL/TSP complex, and its func-
tional interaction with GFRs and integrins, is shown schematically
in Fig. 1.
3. Glycosynapses in various types of cancer cells
Model experiments on the functional role of GM3 and CD9 were
initially performed using ldlD cells transfected with CD9 gene
(ldlD/CD9) [33]. ldlD is a Chinese Hamster Ovary (CHO) cell mutant
with defect of UDP-Gal 4-epimerase, and does not synthesize UDP-
Gal from UDP-Glc. Therefore, all glycoconjugates having Gal,
including GM3, are not synthesized in this mutant unless Gal is
added to chemically-deﬁned ITS culture medium (+Gal) [34]. The
ldlD/CD9 grown under +Gal condition expressed both CD9 and
GM3. Motility of ldlD/CD9 was inhibited under +Gal condition,
but was enhanced under Gal condition, in which GM3 was not
synthesized [33].
Motility of various colorectal cancer cell lines was reduced by
exogenous addition of GM3, when the tumor cells expressed high
CD9 level. Motility of gastric cancer cell line MKN74 was not sus-
ceptible to exogenous GM3 addition, since its CD9 level is low,
but motility became inhibitable by GM3 addition when CD9 level
was increased through CD9 gene transfection. The motility-inhibi-
tory effect of GM3 in CD9-expressing cells was not replaceable
with GM1 or Gb4. These results suggest that co-expression of
GM3 and CD9 is essential to inhibit cell motility. CD9, but not inte-
grins b1, a6, a3, or a4, appears to be the primary target of GM3,
since 3H-labeled photoactivatable GM3 was found to bind prefer-
entially to CD9 expressed in colonic cancer HRT 18 cells under
physiological conditions [17].
In model studies using ldlD/CD9 cells, GM3 and CD9 were found
to interact with integrin a3 under +Gal condition, and were located
in low-density fraction of glycosynapse, as evidenced by co-immu-
noprecipitation. Reversible interaction between CD9 and integrin
a3, and between CD9 and GM3, was observed by laser beam con-
focal microscopy in ldlD cells grown under +Gal vs. Gal condition.
Fig. 1. Interaction of GSLs with tetraspanins, GFRs, and integrins in glycosynapse of tumor cells deﬁnes tumor cell growth, adhesion, and motility. Left panel: Molecular
conformation of GSL. The axis of carbohydrate chain of GSL is perpendicular to the axis of ceramide (N-fatty acyl sphingosine), based on X-ray diffraction pattern of
crystallized cerebroside [47], and on computerized conformational analysis [48]. The outer surface of oligosaccharide of GSL displays higher hydrophobicity than the inner
surface, and consists of a large hydrophobic area adjacent to a small hydrophilic area, providing an ideal binding site for antibodies [49], lectins, and other ligands [50]. A
similar mechanism may apply for binding of GSL to complementary carbohydrates [51], which mediates cell–cell adhesion (see Fig. 2). Right panels: Upper: GSLs, particularly
GM3, interact with: (i) receptors for various growth factors, e.g., EGF, FGF, insulin, cMet, and inhibit the receptor-associated kinase; (ii) integrin receptors a3b1 (for LN5) or
a5b1 (for FN) at glycosynapse, and inhibit cell adhesion-mediated activation of signal transduction through Src family kinases or G-proteins; and (iii) besides processes (i) and
(ii), a different mechanism based on GSL interaction operates between GFRs and integrins. Such functional interaction (cross-talk) is maintained by GM3 and GM2, i.e., cell
adhesion to plates coated with LN5 or FN activates tyrosine kinases associated with FGF or cMet. This process is particularly clear in transformed cells. Lower: Processes (i),
(ii), and (iii) are strongly inhibited or blocked when the glycosynapse contains TSP CD9 or CD81 complexed with GM3, i.e., GM3/CD9/CD81, or TSP CD82 complexed with GM2,
i.e., GM2/CD82. The inhibitory or blocking effect of such complex is particularly clear for tyrosine kinase of FGFR or that of cMet. The blocking effect of GM3/CD9/CD81 on
cross-talk between FGFR and a3b1 is dose-dependent in diploid normal WI38 cells, and is lost completely in transformed VA13 cells due to the loss of CD9/CD81 [23]. GM3
without CD9/CD81, as observed in VA13, or in WI38 with double knockdown of CD9/CD81 by siRNA, causes high cell motility with reduced adhesion [24]. While CD82 was
originally found as metastasis suppressor gene product [52], CD9 was originally found as motility-related protein [53], and they are highly expressed in normal cells and
depleted in close correlation with degree of malignancy, we found that these TSPs are closely associated with GM3 or GM2, and play essential roles in deﬁning tumor cell
motility and invasiveness. The well-known membrane protein caveolin was recently shown to be an important factor deﬁning motility and adhesion when associated with
ganglioside, particularly GM3 or GM2 [16] (see text).
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ity [18].
During this study, CD9 was incidentally found to be soluble in
chloroform/methanol, and recovered mainly at lower phase of
Folch partition [18]. Such properties are very similar to those of
‘‘proteolipid protein” found by Folch over 50 years ago [35].
Composition and function of glycosynapse were further studied
in normal diploid human lung ﬁbroblasts WI38, as compared to
SV40-transformed VA13 cells. GM3 complexed with two TSPs,
CD9 and CD81, was found to be the major component in low-den-
sity fraction of glycosynapse prepared in 1% Brij98 detergent. Level
of such complex was very high in contact-inhibited, slow-growing
WI38, but was greatly reduced in fast-growing VA13 [23].
Comparative Western blotting of low-density fraction of glyco-
synapse as above, from WI38 vs. VA13 cells, showed that level of
FGFR was several times higher in VA13 than in WI38, which was
the opposite of results for level of GM3/CD9/CD81 complex. Levelsof integrins in the same fraction were similar for the two types of
cells. The high level of GM3/CD9/CD81 complex present in WI38
was capable of inhibiting the low level of FGFR tyrosine kinase,
whereas the low level of such complex in VA13 was not capable
of inhibiting the high level of FGFR tyrosine kinase. Thus, FGF-
dependent growth control was well inhibited in WI38, but not in
VA13 [23].
In contrast to growth control mechanism as described above,
there is a separate mechanism for motility control, based on inter-
action of GM3 with integrins. Two types of motility control were
considered: (i) direct effect of GM3, with or without CD9/CD81,
on integrins a3b1 and a5b1, without involvement of FGFR and (ii)
indirect effect of GM3, with or without CD9/CD81, on functional
interaction of these integrins with FGFR tyrosine kinase. In process
(i), motility was strongly inhibited by GM3, through inhibition of
integrin-induced activation of Src kinase. This process was assumed
to result from translocation of C-terminal Src kinase (Csk) from
Fig. 2. GSLs in glycosynapse, involved in cell-cell adhesion. When glycosynapse of
one cell (‘‘a”) contacts glycosynapse of another cell (‘‘b”), cell adhesion occurs by
two mechanisms: (1) GSL-to-GSL interaction, which induces activation of signal
transducer (STD), leading to change of cellular phenotype. In this process,
proteolipid protein (PLP) [18,35] may stabilize conformation of GSL. (2) GSL binds
to GSL-binding protein, which induces activation of STD, leading to change of
cellular phenotype. Each process is further explained below. 1. GSL-to-GSL
interaction, either homotypic or heterotypic. A typical example of homotypic
interaction is cell adhesion based on Lex-to-Lex interaction, observed in autoaggre-
gation of embryonic stem cells D3M, or embryonal carcinoma cells F9, in the
presence of Ca2+ [51,54,55]. Occurrence of such cell adhesion was further conﬁrmed
using D3M or F9 cells whose E-cadherin gene was knocked out. These cells still
displayed strong Lex-dependent autoaggregation and adhesion to Lex GSL-coated
plates which were eliminated by siRNA of fucosyltransferase-9, involved in Lex
synthesis [55]. Lex-to-Lex interaction has been extensively studied and conﬁrmed
by various biophysical procedures, including atomic force microscopy [56],
aggregation of gold glyconanoparticles with Lex [57], and adhesion energy change
based on contact angle (Dhc) of two Lex vesicles [58]. Heterotypic carbohydrate-to-
carbohydrate interactions were found between GM3 and Gg3 [59,60], mediating
adhesion of melanoma cells to lymphoma cells; and between GM3 and LacCer
[61,62], mediating binding of melanoma cells to microvascular endothelial cells, i.e.,
cancer metastatic process [61]. Gold lactosyl nanoparticles were found to inhibit
melanoma cell metastasis in vivo [63]. Interaction of GalCer with sulfatide (3-O-
sulfated GalCer), previously observed on various biophysical bases [64], was found
to mediate adhesion of interfacing membranes of oligodendrocytes [65]. Adhesion
based on both homotypic and heterotypic carbohydrate interaction induces
activation of signal transducers at cytoplasmic site, to alter cellular phenotype. 2.
Structure and function of carbohydrate-binding proteins expressed at cell surface
membrane involved in cell–cell adhesion, or interaction of cell with its microen-
vironment, are well established by many studies. Three major classes of carbohy-
drate-binding proteins are: (i) Selectins (E-, P-, and L-types) having different
structures and functions, and recognizing different glycosyl epitopes containing
LacNAc backbone with fucosyl, sialosyl, or sulfate residue. Selectins play a major
role in inﬂammatory processes and cancer progression, particularly metastasis (for
review see [66,67]). (ii) Sialic acid-binding lectins, abbreviated as ‘‘siglecs”,
expressed at lymphocytes and myelocytes. Their function is to maintain the
internal microenvironment (for review see [68,69]). (iii) Galectins, comprising a
huge number of variants, that recognize galactose or galactosamine. Their functions
are varied, and many are still unclear (for review see [70]).
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cSrc, which competitively inhibits Tyr416, and consequently blocks
Src kinase/Akt/MAPK signal transduction pathway. In process (ii),
GM3 inhibited cross-talk between integrins and FGFR, as indicated
by the observation that cell adhesion to plates coated with laminin-
5 (LN5) or ﬁbronectin (FN) activated FGFR tyrosine kinase. In both
processes (i) and (ii), the inhibitory effect of GM3 was much en-
hanced when GM3 was complexed with CD9/CD81 [24].
4. Reversion of oncogenic to normal cell phenotype by
manipulating GSL/TSP expression in glycosynaptic
microdomain
GM3 expression in chick embryonic ﬁbroblast was closely asso-
ciated with expression of oncogenic phenotype and its reversion.This was initially found in a study with temperature-sensitive mu-
tants of Rous sarcoma virus. GM3 level was high at non-permissive
temperature (41 C) whereby the cells express normal cell pheno-
type. GM3 expression was down-regulated at permissive tempera-
ture (38 C), whereby transformed phenotype was expressed [36].
This study indicated that transformed phenotype and its reversion
are associated with decrease vs. increase of GM3 expression. This
concept was further substantiated by studies with transfection of
Jun oncogene.
Expression of oncogenic phenotype was induced by Jun trans-
fection, and was associated with loss of GM3. In contrast, reversion
to normal cell phenotype was associated with enhanced expres-
sion of GM3 through transfection of GM3 synthase gene. Onco-
genic phenotype and its reversion were determined by positive
vs. negative growth in soft agar, and reduced vs. enhanced anchor-
age-dependent cell adhesion. The reversible phenotypic change
associated with the presence vs. absence of GM3 was closely re-
lated to formation of GM3/CD9/integrin complex. Only absence
vs. presence of GM3 appeared to be the major factor deﬁning phe-
notypic changes of transformation vs. reversion, since CD9 and
integrin did not show major changes, and were consistently pres-
ent [37].
Oncogenic phenotype and its reversion associated with GM3 or
GM2 complexed with TSP CD9 or CD82 in glycosynapse were fur-
ther studied in human tumor cells, as in the following three
examples.
1. GM3 is highly expressed in human bladder benign, non-invasive
tumor KK47 cells, but GM3 level is very low in highly malignant,
invasive bladder cancer YTS1 cells. Both cell lines express TSP
CD9, and integrin a3b1. a3/CD9 interaction is much stronger
in benign KK47 than in YTS1. This difference is due to the pres-
ence of GM3 in KK47, vs. its absence in YTS1. Phenotypic rever-
sion from YTS1 with high motility, to phenotype similar to that
of benign KK47 with low motility, was caused by exogenous
addition of GM3 to YTS1, whereby a3/CD9 interaction was
strongly enhanced, and Src kinase activity was strongly reduced.
Reduction of Src kinase in glycosynapse is due to translocation of
Csk into glycosynaptic domain, whereby Src tyrosine kinase was
inhibited. Thus, oncogenic transformation and its reversion can
be explained by differences in glycosynaptic organization [19].
2. In contrast to KK47 and YTS1 cells as above, normal bladder epi-
thelial cells HCV29 express ganglioside GM2 and TSP CD82 as
major components, which form stable complexes in glycosyn-
apse. Such complex inhibits cMet tyrosine kinase activity
induced by hepatocyte growth factor (HGF). Since highly malig-
nant bladder cancer YTS1 has no CD82 but does have low level
of GM2, both growth and motility of YTS1 are very high, inde-
pendent of HGF stimulation. When YTS1 was transfected with
CD82 gene, to get high level of CD82, growth and motility were
converted to phenotype similar to that of HCV29, i.e., regulated
cell growth and low motility, through acquired HGF-dependent
cMet tyrosine kinase activity [32].
3. Our studies so far, described above, are focused on the effect of
single ganglioside GM3, or GM2, expressed in glycosynapse, and
the mechanism of either GM3 or GM2 interacting with TSPs,
GFRs, and integrins. However, various normal and tumor cells
often express both GM3 and GM2, or other GSLs. Normal blad-
der epithelial HCV29 cells express both GM2 and GM3,
although GM2 is the major component. When GM3 was added
to HCV29, HGF-induced cell motility and growth through cMet
tyrosine kinase were strongly inhibited. This was found to be
based on Ca2+-dependent formation of a heterodimer between
GM2 and GM3, as evidenced by electrospray mass spectrome-
try, and by speciﬁc reactivity with newly established mAb
8E11, directed to the heterodimer but not to GM2 or GM3 alone.
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was further conﬁrmed by model experiments using ldlD cells
transfected with CD82 gene and with GM2 synthase (b4GalNAcT4)
gene. Growth of ldlD/CD82/b4GalNAcT4 was inhibited under con-
ditions causing appropriate GM2 and GM3 level, when the double
transfectant was grown in ITS medium added with 20 lM Gal and
200 lMGalNAc. Such cells were clearly stained by mAb 8E11, indi-
cating the expression of GM2/GM3 heterodimer. Motility and
growth of various tumor cells expressing cMet were reduced to a
level similar to that of normal cells by treating cells with nanopar-
ticles coated with GM2/GM3 heterodimer [38]. Thus, treatment of
tumor cells (in this case bladder cancer) with nanoparticles bearing
GM2/GM3 heterodimer is a novel technology to cause reversion of
tumor cells to normal cell phenotype.5. Speciﬁc GSLs in glycosynapse mediate epithelial–
mesenchymal transition process
Studies initiated by Hay and co-workers [39,40], and her follow-
ers, during three decades, showed that epithelial cells change their
morphology, growth, and motility when they come in contact with
extracellular matrix, or with mesenchymal cells. Consequently,
expression of epithelial cell molecules declines, and molecules
characteristic of mesenchymal cells increase. This process, termed
‘‘epithelial–mesenchymal transition” (EMT), has been widely rec-
ognized as a basic process in embryonic development (for review
see [41]), and in cancer progression (for review see [42,43]). While
changes of glycosylation in developmental processes and cancer
progression are well established, no studies have addressed the
functional role of GSLs in membrane microdomain, which may
mediate EMT.
We recently demonstrated involvement of GSLs in the EMT pro-
cess, using three epithelial cell lines. Treatment of these cells with
transforming growth factor b (TGFb), the EMT inducer, (i) down-
regulated expression of a major epithelial cell marker, E-cadherin;
(ii) up-regulated expression of mesenchymal cell markers vimen-
tin, ﬁbronectin, and N-cadherin; (iii) enhanced haptotactic cell
motility; and (iv) converted epithelial to ﬁbroblastic morphology.
The same changes of these cell lines were also induced by treat-
ment with EtDO-P4, the GlcCer synthase inhibitor, which depletes
all GSLs derived from GlcCer.
A close association of speciﬁc GSL changes with EMT process,
induced by TGFb or EtDO-P4, is indicated by the following ﬁndings:
(a) The enhanced cell motility of EtDO-P4-treated cells was
abrogated by exogenous addition of GM2 or Gg4 (Galb3Gal-
NAcb4Galb4Glcb1Cer) (gangliotetraosylceramide), but not GM1
or GM3, in all three cell lines. (b) TGFb treatment caused depletion
or reduction of Gg4 or GM2 in NMuMG, and reduction of GM2 in
HCV29. (c) Exogenous addition of Gg4 inhibited TGFb-induced
changes of morphology, motility, and levels of epithelial and mes-
enchymal markers. These observations indicate that speciﬁc GSLs
play key roles in deﬁning phenotypes associated with EMT and
its reverse process, i.e., mesenchymal-to-epithelial transition [44].
A number of studies during the past decade clearly indicate that
molecular changes similar to those in EMT process can also be in-
duced by hypoxia (low O2) (for reviews see [45,46]). Results of our
recent study on Gg4 expression in mouse epithelial NMuMG cells
indicate that: (i) gene expression of b1–3 galactosyltransferase-4
(b3GalT4), which adds Gal to Gg3 (GalNAcb4Galb4Glcb1Cer) (gan-
gliotriaosylceramide) to make Gg4, was strongly reduced by TGFb
treatment, as detected by glycogene array analysis and real-time
RT-PCR; (ii) similarly to TGFb treatment, culturing of cells under
hypoxia condition, or in the presence of CoCl2, caused activation
of hypoxia-inducible factors (HIF), and also induced EMT process:
enhancement of cell motility, reduced expression of epithelial mar-ker molecules together with enhancement of mesenchymal mole-
cules, and change of cell morphology; and (iii) associated with
these changes, Gg4 level and b3GalT4 gene expression were re-
duced. These ﬁndings further support involvement of GSLs in
EMT process and hypoxia (Guan F. et al., JBC, under review).
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